Ms. Julia Becker reports

TEMPRAMED SIGNS AGREEMENT FOR EXCLUSIVE DISTRIBUTION PARTNERSHIP IN BRAZIL, ONE OF THE LARGEST DIABETES AND BIOLOGICS MARKETS GLOBALLY

Tempramed Technologies Ltd. has signed an agreement with Mobil Saude Comercial Ltda. regarding the exclusive distribution of Tempramed products in Brazil.

The agreement marks another important step in Tempramed's strategy to expand throughout Latin America and follows the company's recent distribution initiatives in Central America and other international markets. Under the contemplated agreement, Mobil Saude is expected to distribute Tempramed's portfolio initially including Vivi Cap, with the potential addition of Vivi Med, Vivi Epi and Vivi Cap Smart as the partnership develops.

The arrangement contemplates a three-year exclusive distribution framework with minimum annual purchase commitments, reflecting the parties' expectation of growing market demand. Exclusivity would become effective following placement and full prepayment of the initial order.

Brazil represents one of the largest health care and diabetes markets globally, with millions of patients relying on temperature-sensitive medications including insulin, GLP-1 therapies, biologics and epinephrine auto-injectors. The diabetes market alone reached $2.15-billion (U.S.) in 2025 and is forecast to surpass $3.09-billion (U.S.) by 2034, reflecting a compound annual growth rate of 3.96 per cent across the forecast period. Growing awareness around medication efficacy, climate exposure and chronic disease management continues to drive demand for practical medication-protection solutions.

Mobil Saude is a Brazilian health care commercialization and distribution company focused on expanding access to innovative health care technologies across Brazil's pharmacy, health care and medical distribution sectors. The company is headquartered in Sao Paulo state, and is expected to support regulatory, commercial and launch activities throughout the Brazilian market.

"This agreement represents an important milestone in our expansion strategy across Latin America," said Ron Nagar, chief executive officer of Tempramed. "Brazil is one of the world's largest and most strategically important markets for diabetes care and injectable therapies. Partnering with Mobil Saude has the potential to significantly expand access to our products while strengthening our commercial presence in the region."

Commercial expansion supported by strengthening Brazilian intellectual property position

The agreement follows Tempramed's recent announcement that the Brazilian Patent Office formally granted the company's patent covering core innovations underpinning Vivi Box, Tempramed's next-generation multimedication storage platform expected to launch commercially at the end of 2026 (see press release dated April 7, 2026).

The granted patent strengthens Tempramed's intellectual property position in Brazil through October, 2039, and supports the company's long-term strategy to commercialize a broader ecosystem of temperature-controlled medication solutions across South America. The patent includes key elements of Tempramed's proprietary thermal insulation and smart monitoring architecture, including portable cold storage, protection during power interruptions and cloud-connected monitoring capabilities.

Management believes the combination of expanding distribution infrastructure and strengthening IP protection positions Tempramed to capitalize on growing demand for medication protection technologies throughout Latin America.

Engages German marketing support

As of May 28, 2026, subject to the approval of the Canadian Securities Exchange, the company has engaged Plutus Invest & Consulting GmbH to provide investor programs to increase awareness about the company in Europe for a 12-month term. The program includes strategic planning, content creation, ad placement, media buying and execution.

The company agrees to pay Plutus 100,000 euros immediately for the entirety of the program. Plutus is at arm's length from Tempramed and currently has no interest in the company. Marco Messina is a managing director of Plutus, and will be responsible for all activities related to the company.

About Mobil Saude Comercial Ltda

Mobil Saude Comercial is a Brazil-based health care commercialization and distribution company focused on bringing innovative medical and health care technologies to the Brazilian market. Headquartered in Sao Caetano do Sul, Sao Paulo province, Mobil Saude operates within one of Brazil's largest health care and pharmaceutical regions, and is strategically positioned to support nationwide commercialization initiatives across retail pharmacy, medical distribution and health care provider channels.

The company's activities include health care product commercialization, regulatory co-ordination, market access support, distribution management and strategic business development for international health care brands seeking entry into Brazil. Through its growing network and market relationships, Mobil Saude is positioned to support product launches, physician engagement, pharmacy penetration and long-term commercial scale-up within Brazil's large and rapidly growing chronic care market.

About Tempramed Technologies Ltd.

Tempramed is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered, thermal insulation devices that work 24-seven without batteries or external power. With a product line already in market including Vivi Cap, Vivi Cap Smart, Vivi Epi and Vivi Med, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed will continue to expand globally offering a solution for medication protection and adherence.

We seek Safe Harbor.